✦ LIBER ✦

Cost Effectiveness of Fracture Prevention in Postmenopausal Women Who Receive Aromatase Inhibitors for Early Breast Cancer

✍ Scribed by Shih, Y.C.T.; Chien, C.R.; Shen, Y.

Book ID: 122353339
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 66 KB
Volume: 24
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2013.01.009

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1146 POSTER Cost-effectiveness of zoledr

1146 POSTER Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom

✍ F. Logman; B. Heeg; M.F. Botteman; A.A. Marfatia; B.A. van Hout 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 63 KB

S62– Cost-effectiveness of aromatase inh

S62– Cost-effectiveness of aromatase inhibitors versus tamoxifen in postmenopausal women with early breast cancer positive for hormonal receptors

✍ Oscar Andrés Gamboa Garay; Sandra Díaz; Oscar Garcia; Fernando Perry; Mario Garc 📂 Article 📅 2010 🏛 SAGE Publications 🌐 English ⚖ 48 KB

Bone health in a prospective cohort of p

Bone health in a prospective cohort of postmenopausal women receiving aromatase inhibitors for early breast cancer

✍ Sònia Servitja; Xavier Nogués; Daniel Prieto-Alhambra; María Martínez-García; La 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Vitamin D deficiency and bone mineral de

Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer

✍ Xavier Nogues; Sonia Servitja; Maria Jesus Peña; Daniel Prieto-Alhambra; Rosa Na 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 406 KB

Summary of aromatase inhibitor clinical

Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer

✍ Aman U. Buzdar; R. Charles Coombes; Paul E. Goss; Eric P. Winer 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

Five years of adjuvant therapy with tamoxifen was considered the gold-standard treatment for postmenopausal women with estrogen receptor-positive breast cancer for many years. Data from a core group of clinical trials investigating the safety and efficacy of aromatase inhibitors (AIs) have challenge

The role of aromatase inhibitors as adju

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women

✍ Henning T. Mouridsen; Nicholas J. Robert 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 181 KB